From cold to hot: Perception of the use and impact of QSP in immuno-oncology – A survey of the community and stakeholders –

Vincent Lemaire and Fei Hua (on behalf of the ISoP QSP I-O Working Group)

Rosa webinar, Jan 18th, 2023

Clinical Pharmacology & Therapeutics

White Paper | 🔂 Open Access | 💿 🛊 😒

From Cold to Hot: Changing Perceptions and Future Opportunities for Quantitative Systems Pharmacology Modeling in Cancer Immunotherapy

Vincent Lemaire, David Bassen, Mike Reed, Roy Song, Samira Khalili, Yi Ting (Kayla) Lien, Lu Huang, Aman P. Singh, Spyros Stamatelos, Dean Bottino 📉, Fei Hua 🔀

First published: 25 October 2022 | https://doi.org/10.1002/cpt.2770

The ISoP QSP I-O Special Interest Working Group

Members (at the time of the survey):

- Fei Hua (Applied Biomath)
 -- past chair
- Dean Bottino (Takeda) past chair
- Brian Smith (BMS)
- Vincent Lemaire (Genentech)
- David Bassen (Applied Biomath)
- Mike Reed (Rosa)
- Roy Song (GSK)
- Samira Khalili (Takeda) current chair
- Kayla Lien (Genentech)
- Lu Huang (BMS)
- Aman Singh (Takeda)
- Spyros Stamatelos (Bayer)

- Ignacio Troconiz (U. de Navarra) – current chair
- Michael Zager (Pfizer)
- Loveleena Bansal (GSK)
- Andrew Stein (Novartis)
- Yougan Cheng (BMS)
- Jane Bai (FDA)
- Wenlian Qiao (Pfizer)
- John Tolsma (RES)
- Andrzej Kiersek (Certara)
- Lei Sun (Alkermes)
- Paolo Vicini (Kymab)

Mission:

- Focus on maximizing impact of QSP in I-O Drug discovery, development, and use in patients.
- Exchange of ideas and precompetitive knowledges among different companies, academia and clinicians to improve I-O QSP model development.
- Promote mechanistic modeling in I-O and dissemination of modeling in cross-disciplinary forums (in particular for non-modeling scientists and decision makers in immuno-oncology).
- Provide expert feedback and guidance for the modeling community in I-O.

Immune system and cancer

New York Times - July 29, 1908 ERYSIPELAS GERMS ASCURE FOR CANCER

Dr. Coley's Remedy of Mixed Toxins Makes One Disease Cast Out the Other.

MANY CASES CURED HERE

Physician Has Used the Cure for 15 Years and Treated 430 Cases— Probably 150 Sure Cures.

Following news from St. Lou's that two men have been cured of cancer in the City Hospital there by the use of a fluid discovered by Dr. William B. Coley of New York, it came out yesterday that nearly 100 cases of that supposely incurable disease have been cured in this city during the last few years, all through the use of the fluid discovered by Dr. Coley.

Image from following paper: Oiseth SJ, Aziz MS. Cancer immunotherapy: a brief review of the history, possibilities, and challenges ahead. *J Cancer Metastasis Treat* 2017;3:250-61. http://dx.doi.org/10.20517/2394-4722.2017.41


Hallmarks of Cancer: The Next Generation

Douglas Hanahan^{1,2,*} and Robert A. Weinberg^{3,*}


¹The Swiss Institute for Experimental Cancer Research (ISREC), School of Life Sciences, EPFL, Lausanne CH-1015, Switzerland ²The Department of Biochemistry & Biophysics, UCSF, San Francisco, CA 94158, USA

³Whitehead Institute for Biomedical Research, Ludwig/MIT Center for Molecular Oncology, and MIT Department of Biology, Cambridge, MA 02142, USA


*Correspondence: dh@epfl.ch (D.H.), weinberg@wi.mit.edu (R.A.W.) DOI 10.1016/j.cell.2011.02.013



Immuno-oncology has experienced unprecedent diversity, scale, and complexity



PD-(L)1 and CTLA-4 clinical activity



Classification of immuno-oncology agents

https://www.mckinsey.com/industries/life-sciences/our-insights/delivering-innovation-2020-oncology-market-outlook

Franklin MR, Platero S, Saini KS, *et al* Immuno-oncology trends: preclinical models, biomarkers, and clinical development. *Journal for ImmunoTherapy of Cancer* 2022;**10**:e003231. doi: 10.1136/jitc-2021-003231

Range of ODE models in drug R & D

Empirical PK/PD

 Try to find a minimal model to describe the observed data

Mechanistic PK/PD

• Integrate the pharmacology of the drug, e.g. binding to targets

Quantitative Systems Pharmacology (QSP)


- Describe disease biology
- Describe downstream effects after drug engagement

Interpolation

Extrapolation

Knowledge captured \uparrow Model complexity \uparrow Model identifiability \downarrow

Anatomy of IO QSP Model



The survey

The survey form was live for 4 months in Feb-June 2021

Use and impact of immuno-oncology QSP modeling in the pharma/biotech industry

Quantitative systems pharmacology (QSP) models describe complex biology and mode of action of drugs by integrating a variety of data including in vitro, in vivo data, and data from different compounds. QSP models in immuno-oncology (I-O) have been used to support target evaluation, drug property optimization, efficacious dose predictions, dose and schedule optimization, biomarker identification, patient population selection and combination strategy.

In this survey, we want to identify what areas QSP modeling has influenced your I-O programs and potential improvement/development you want to see in QSP modeling so that it can further help your programs.

The goal of the survey was to


- Evaluate the current impact of QSP in immunooncology
- Identify areas of strength and areas that would need improvement
- Get a sense for where the field may be going in the future.

16 questions in 5 categories:

- 1. Background
- 2. Current use and impact of QSP in I-O
- 3. Current challenges of QSP in I-O
- 4. Future directions of QSP in I-O
- 5. Additional thoughts


Survey respondents demographics

134 respondents from industry and academia











Survey respondents roles





Types of modeler

(split by company size)




Applications of QSP in I-O






Top areas:

- 1. Dosing/scheduling
- 2. Combinations




Top areas: 1. Dosing/scheduling¹ 2. Combinations²

Top perceived applications correlate well with the frequency of publications in these domains



bottom areas:


- 1. Portfolio prioritization
- 2. Not these questions
- 3. Candidate selection
- 4. Reverse translation
- 5. Target validation



bottom areas:

- 1. Portfolio prioritization
- 2. Not these questions
- 3. Candidate selection
- 4. Reverse translation
- 5. Target validation

Candidate selection & Target validation: Early development Reverse translation: New area Portfolio prioritization: Strategic decision based on multiple inputs




Most conflicting areas:


1. Biomarkers

Perceived impacts of QSP in I-O

What have been the contributions of QSP in your I-O projects?



What have been the contributions of QSP in your I-O projects?




Top impacts:

- 1. Critical + Regulatory use
- 2. Helpful but no regulatory use
- 3. Helpful + regulatory use

The survey respondents perceive the contribution of QSP positively, with most of the responses ranging from QSP leading to critical impact on projects to being useful to projects


What have been the contributions of QSP in your I-O projects?



Bottom impacts:

- 1. Decision opposite to QSP
- 2. Unsure
- 3. No QSP performed

What have been the contributions of QSP in your I-O projects?





Contribution of QSP (all classes)

Most conflicting impacts:

- 1. Critical + Regulatory use
- 2. Helpful but no regulatory use
- 3. Helpful but no regulatory use

Challenges of applying QSP in I-O






Top Challenges:

1. Not enough data


2. Timeline is too long

3. Lacking validation




Top Challenges: 1. Not enough data 2. Timeline is too long 3. Lacking validation

Not enough data: Widespread difficulty for all modeling approaches Timeline is too long: Complexity Lacking validation: No generally accepted validation process




Top Challenges: 1. Not enough data 2. Timeline is too long 3. Lacking validation

Not enough data: Widespread difficulty for all modeling approaches Timeline is too long: Complexity Lacking validation: No generally accepted validation process



Top Challenges: 1. Not enough data 2. Timeline is too long 3. Lacking validation

Not enough data: Widespread difficulty for all modeling approaches Timeline is too long: Complexity Lacking validation: No generally accepted validation process




Bottom Challenges:

1. Not needed

2. Budget is too high


3. Too complicated


Difference in perception between QSP modelers and non-QSP people



Future directions of QSP in I-O


What are the key I-O questions that QSP could address in your programs in the future?







32

Unique aspects of applying QSP in I-O vs. other disease areas









species difference

Combinations



human immune response





Key takeaway from the survey results

- Overall, the survey respondents perceive the contribution of QSP positively, with most of the responses ranging from QSP leading to critical impact on projects to being useful to projects.
- QSP models seem to be currently most often used to help with dosing/scheduling of clinical studies; while use in early drug discovery such as target validation and candidate selection is lower at the moment but is expected to grow in the future.
- The top 3 challenges for IO QSP model development identified in the survey are limited data, long timeline and insufficient validation of the models.
- The survey revealed differences in perception on the impact of QSP in I-O between QSP modelers and others suggesting QSP modelers need to improve education and communication to their stakeholders.
- For the future, people in general consider that QSP models can further increase their contribution to IO programs in all areas; while helping with combination therapy is being selected by the highest number of respondents.
- A lot of room to grow, either in terms of communication, applying QSP more widely, more transparent validation criteria.

THANK YOU!